The Degreaser Everyone Tolerates

An eight-hour TWA is an average, and an average conceals the exposure that causes harm. On an open-top vapor degreaser, exposure is task-driven: it peaks when parts enter and leave the vapor zone, when the vapor blanket is disturbed by a draft or a fan, when the unit idles hot without a cover, and during cleanout. A TWA of 12 ppm is entirely compatible with ten-minute peaks of 60 to 100 ppm, which is where the headaches come from and which is the number a short-term limit addresses.

What is missing:

• Short-term and peak sampling in the breathing zone of each of the six operators, plus task-based sampling of load, unload, and cleanout separately.
• A defensible sampling strategy: worst-case worker first, enough samples to have statistical confidence that the group mean sits below the limit (in practice six or more per similar exposure group, not one composite).
• Dermal assessment. The dermatitis is a data point, not an inconvenience. Nitrile gloves have finite breakthrough against this solvent and a splash on the forearm is a real route. Skin exposure is not captured by any air sample, and the air limit does not protect against it.
• Verification of the current OEL itself. Confirm the 10 ppm corporate value against current authoritative guidance and any supplier data; a corporate limit set years ago may no longer be the most protective available.
• Equipment condition data: exhaust flow against design, cooling-coil temperature, freeboard ratio, cover use when idle, and whether parts are dried in or above the vapor zone.

Interpretation for management: we do not have a marginal exposure problem, we have an uncharacterized one. One sample above a limit with no peak data does not support a conclusion of 'just over'; it supports a conclusion of 'we cannot yet say how bad the peaks are.' That distinction drives the control decision.

Sequence, not a single fix:

Days 0–30 (immediate, no capital): cover the unit whenever idle; verify exhaust flow with a velometer against design and repair duct leaks; confirm cooling-coil temperature is at setpoint; stop drying parts above the vapor zone; restrict the degreaser to the six trained operators; issue gloves selected against the actual solvent with breakthrough data and add face/forearm protection; start medical surveillance targeting the neurological, hepatic, and dermatological endpoints for all six operators; post the sampling results and explain them.

Days 30–120: install the $60,000 local exhaust retrofit with a documented commissioning airflow test, then re-sample with task-based and short-term methods. If post-control results fall below roughly 50 percent of the limit with no short-term exceedance, continue and re-verify quarterly.

6–18 months: capital case for enclosure or aqueous substitution.

Why respirators are not the answer:

• They protect only the wearer, so the source stays uncontrolled and every unprotected entrant - maintenance, visitors, the next hire - is exposed.
• They do nothing for the dermal route, and you already have a dermatitis case proving that route is live.
• They fail on fit, facial hair, and donning discipline, and each failure is invisible.
• They are a recurring cost and a recurring paperwork exposure: medical clearance, annual fit testing, cartridge change schedules, and training, all of which are heavily cited when done incompletely.
• Most importantly, they are appropriate only after feasible engineering controls have been implemented. Choosing them first inverts the hierarchy for cost convenience.

If used at all, an interim program includes: medical clearance, annual quantitative fit testing, a written cartridge change schedule based on use conditions, storage and inspection, and documented training - not a box of masks in the tool crib.

Triggers that commit you to substitution, agreed in advance with operations: post-engineering TWA still above 50 percent of the limit; any short-term or peak exceedance; any new health effect reported by an operator; a change in the supplier or regulatory limit; or failure to sustain exhaust performance. Writing these down now prevents the decision from being renegotiated every year.

Business case outline:

• Fully loaded cost of the current path: respirator program (the $6,000 of cartridges understates it - add medical clearance, fit testing, training, and administrative time, realistically $15,000 or more), quarterly sampling, medical surveillance, exhaust maintenance, and solvent purchase and disposal.
• Enclosed and aqueous systems typically cut solvent consumption substantially, so there are operating savings, not just capital cost.
• Risk-cost: a dermatitis or neurological claim from a known exposure you documented and did not abate is expensive and difficult to defend, as is a per-employee citation exposure.
• Address the $2.1 million contract head-on. It is a customer relationship risk to be managed, not a reason to retain an uncontrolled exposure. Bring the customer's process engineers into qualification early; customers frequently accept a cleaning change when they see the data, and nine months of lead time is only a problem if you start in month nine.

The two symptomatic operators and the dermatitis:

• Refer all three to the occupational physician now; do not diagnose or speculate yourself.
• Determine recordability: a skin disorder diagnosed by a physician is recordable, and the headache reports may or may not be - evaluate each against the criteria rather than deciding by convenience.
• Evaluate work restriction and, if the physician recommends it, remove them from exposure on full pay while you fix the source.
• Keep medical information confidential and separate from the operational file; supervisors get restrictions, not diagnoses.
• Document that exposure was characterized and reduced - this is the record that shows you responded when you learned of harm.